What is a surrogate marker for optimal dialysis?

To find a surrogate marker to obtain optimal dialysis delivery from the viewpoint of nutrition, 180 maintenance hemodialysis patients (109 males/71 females) were enrolled between October 1999 and June 2006 at our kidney center. In the 449 hemodialysis treatments, ultrapure dialysis solutions and high-flux synthetic membranes were utilized. Parameters were measured by Kt/V(urea) and postdialysis urea rebound, Kc (the cellular membrane clearance for urea), urea clear space (CS), %creatinine generation rate, %lean body mass, total body water, and so on.

Dialysis adequacy targets in elderly chronic peritoneal dialysis patients.

We performed the present study to determine dialysis adequacy targets for improved clinical outcome in elderly chronic peritoneal dialysis (PD) patients. Since 1993, 19 elderly patients (14 men, 5 women; 5 with diabetes, 14 without diabetes; mean age: 78.9 +/- 7.

Dialysis dose and nutrition in Japanese peritoneal dialysis patients.

In the present study, we tried to determine the relationship between dialysis dose and nutrition in PD patients. We enrolled 100 Japanese outpatients, including 11 diabetic patients, who were on continuous ambulatory peritoneal dialysis [CAPD (n = 74)] and automated peritoneal dialysis [APD (n = 26)] at 49 local hospitals. In all patients, a peritoneal function test (PET) was performed using the PD NAVI software (JMS, Hiroshima, Japan).

Serum matrix metalloproteinase-3 in hemodialysis patients with dialysis-related amyloidosis.

Background: Matrix metalloproteinase-3 (MMP-3) has been linked to osteoarticular destruction in rheumatic arthritis. To investigate the role of MMP-3 in dialysis-related amyloidosis (DRA), we determined serum MMP-3 in long-term hemodialysis (HD) patients with and without clinical manifestations of DRA.

Methods: Thirty-three subjects (63% female, 3% diabetic) enrolled in the study between September 2001 and June 2003.